ClinicalTrials.gg
WithdrawnNCT04128852PROGRESSUpdated Feb 13, 2024

Post Marketing Clinical Follow up Study for MagnetOs Putty in Patients With Degenerative Disc Disease

An interventional study of MagnetOs Putty in Degenerative Disc Disease, sponsored by Kuros Biosurgery AG. Withdrawn. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Kuros Biosurgery AG · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
redirected funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
25 Years to 75 Years
Sex
All
01

Study summary

This study is a post-marketing clinical follow-up study for MagnetOs Putty. MagnetOs Putty is a synthetic bone-like material which is routinely used by surgeons as a treatment for patients with degenerative disc disease who will undergo surgery for spinal fusion (extreme lateral interbody fusion (XLIF). MagnetOs Putty will be used according to the instructions for use.

02

Conditions studied

  • Degenerative Disc Disease

Keywords

  • Spinal Fusion
03

In context

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Kuros Biosurgery AG is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written by the patient.
  2. Male or female patient ≥ 25 up to and including 75 years old.
  3. Patients with degenerative disc disease with up to grade 1 spondylolisthesis and with leg pain requiring 1 to 3 level laminectomy and a single/two-level fusion (L2 - S1). Degenerative disc disease is defined by the presence of one or more of the following:

    1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
    2. osteophyte formation of facet joints or vertebral endplates,
    3. decreased disc height by > 2 mm, but dependent upon the spinal level,
    4. scarring/thickening of ligamentum flavum, annulus fibrosis or facet joint capsule,
    5. disc degeneration and/or herniation,
    6. facet degeneration,
    7. vacuum phenomenon.
  4. Patients with an Oswestry Disability Index (ODI) score ≥ 30.
  5. Patients with a Visual Analogue Scale (VAS) leg score ≥ 40.
  6. Failed conservative treatment (physical therapy, bed rest, medications, spinal injections or transcutaneous electrical nerve stimulation) for a period of 6 months prior to study enrollment.

Exclusion criteria

Exclusion Criteria:

Per the current Instruction For Use, MagnetOs Putty must not be used in the following clinical situations:

  1. To treat conditions in which general bone grafting is not advisable.
  2. In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilisation is not possible).
  3. In case of significant vascular impairment proximal to the graft site.
  4. In case of severe metabolic or systemic bone disorders that affect bone or wound healing.
  5. In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  6. When intraoperative soft tissue coverage is not planned or possible.
  7. In direct contact with the articular space.
  8. In case of treatment with medication interfering with the calcium metabolism.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    MagnetOs Putty

    MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.

    Device: MagnetOs Putty

Interventions

  • DeviceMagnetOs Putty

    MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).

06

What researchers measure

Primary outcomes

  1. Radiographic interbody fusion by CT scan

    The rate of interbody fusion assessed by CT-scan at Month 12. Radiographic fusion using CT-scan will be defined by an independent radiology expert at Month 12 post-surgery and determined by evidence of bridging trabeculae or continuous bony connection between superior and inferior vertebral body.

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Dec 2022, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2019
First posted
Oct 16, 2019
StartActual
Nov 11, 2020
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2023
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04128852
Lead sponsor
Kuros Biosurgery AG
Collaborators
Factory CRO, The London Clinic, Kuros BioSciences B.V.
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Nov 11, 2020
Primary completion
Dec 2022 (estimated)
Completion
Dec 2023 (estimated)
Last update
Feb 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion